Department of Clinical Pharmacology, National Institute of Oncology, Chest and Abdominal Tumours Chemotherapy "B", Budapest, Hungary.
Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
Pathol Oncol Res. 2022 Jul 11;28:1610383. doi: 10.3389/pore.2022.1610383. eCollection 2022.
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified based on the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The professional guideline primarily reflects the resolutions and recommendations of the current ESMO, NCCN and ABC5, as well as that of the St. Gallen Consensus Conference statements. The recommendations cover classical prognostic factors and certain multigene tests, which play an important role in therapeutic decision-making. From a didactic point of view, the text first addresses early and then locally advanced breast cancer, followed by locoregionally recurrent and metastatic breast cancer. Within these, we discuss each group according to the available therapeutic options. At the end of the recommendations, we summarize the criteria for treatment in certain rare clinical situations.
本指南文本基于第 4 次匈牙利乳腺癌共识会议所接受的建议,并根据国际咨询意见和在中东欧肿瘤学会框架内召开的会议进行了修改。该专业指南主要反映了当前 ESMO、NCCN 和 ABC5 以及圣加仑共识会议声明的决议和建议。这些建议涵盖了经典的预后因素和某些多基因检测,这些因素在治疗决策中起着重要作用。从教学的角度来看,本文首先讨论早期乳腺癌,然后讨论局部晚期乳腺癌,接着讨论局部区域复发和转移性乳腺癌。在这些疾病中,我们根据现有的治疗选择讨论了每个组别的内容。在建议的最后,我们总结了某些罕见临床情况下的治疗标准。